Aligos Therapeutics (ALGS) Retained Earnings (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Retained Earnings came in at -$665.2 million in Q1 2026, down 15.71% YoY from -$789.3 million in Q1 2025, and down 142245.51% on a QoQ basis from $468000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Retained Earnings (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Retained Earnings data on file, last reported at -$665.2 million in Q1 2026.
- Quarterly Retained Earnings fell 15.71% year-over-year to -$665.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$665.2 million (down 15.71% YoY) and the FY2025 annual result came in at $468000.0, up 3.77% from the prior year.
- Retained Earnings eased to -$665.2 million in Q1 2026, from $468000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $497000.0 in Q3 2023 to a low of -$665.2 million in Q1 2026.
- A 5-year average of -$368.1 million and a median of -$422.1 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 149101.32% — and 2023, when it soared 100.13%.
- Tracing ALGS's Retained Earnings over 5 years: stood at -$399.1 million in 2022, then slipped by 21.97% to -$486.8 million in 2023, then surged by 100.09% to $451000.0 in 2024, then advanced by 3.77% to $468000.0 in 2025, then plunged by 142245.51% to -$665.2 million in 2026.
- The last three Retained Earnings figures came in at -$665.2 million (Q1 2026), $468000.0 (Q4 2025), and -$622.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | -666.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -666.75 Mn |
| Mar 31, 2026 | -665.24 Mn |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | -622.32 Mn |
| Jun 30, 2025 | 420,000.00 |
| Mar 31, 2025 | -574.90 Mn |
| Dec 31, 2024 | 451,000.00 |
| Sep 30, 2024 | -535.86 Mn |
| Jun 30, 2024 | -516.60 Mn |
| Mar 31, 2024 | -521.70 Mn |
| Dec 31, 2023 | -486.80 Mn |
| Sep 30, 2023 | 497,000.00 |
| Jun 30, 2023 | -440.86 Mn |
| Mar 31, 2023 | -422.07 Mn |
| Dec 31, 2022 | -399.12 Mn |
| Sep 30, 2022 | -377.20 Mn |
| Jun 30, 2022 | -358.60 Mn |
| Mar 31, 2022 | -338.69 Mn |
| Dec 31, 2021 | -303.07 Mn |
| Sep 30, 2021 | -265.36 Mn |